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eliable and quantitative assays to
measure in vivo autophagy are essential. Currently, there are varied methods
for monitoring autophagy; however,
it is a challenge to measure “autophagic flux” in an in vivo model system.
Conversion and subsequent degradation
of the microtubule-associated protein 1
light chain 3 (MAP1-LC3/LC3) to the
autophagosome associated LC3-II isoform can be evaluated by immunoblot.
However, static levels of endogenous
LC3-II protein may render possible misinterpretations since LC3-II levels can
increase, decrease or remain unchanged
in the setting of autophagic induction.
Therefore, it is necessary to measure
LC3-II protein levels in the presence
and absence of lysomotropic agents that
block the degradation of LC3-II, a technique aptly named the “autophagometer.” In order to measure autophagic
flux in mouse skeletal muscle, we treated
animals with the microtubule depolarizing agent colchicine. Two days of 0.4
mg/kg/day intraperitoneal colchicine
blocked autophagosome maturation to
autolysosomes and increased LC3-II protein levels in mouse skeletal muscle by
>100%. The addition of an autophagic
stimulus such as dietary restriction or
rapamycin led to an additional increase
in LC3-II above that seen with colchicine alone. Moreover, this increase was
not apparent in the absence of a “colchicine block.” Using this assay, we evaluated the autophagic response in skeletal
muscle upon denervation induced atrophy. Our studies highlight the feasibility
of performing an “in vivo autophagometer” study using colchicine in skeletal
muscle.
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Introduction
Autophagy is a nonspecific and bulk
degradation process which delivers cytoplasmic materials including damaged
organelles, toxic protein aggregates and
intracellular pathogens to lysosomes via
double-membraned organelles termed
autophagosomes.1 Autophagy is highly
dynamic and regulated. Autophagic activity is usually low under basal conditions,
but can be markedly increased by stimuli
such as nutrient deprivation, hypoxia, cellular stress, infection and pharmacological agents such as rapamycin. Defects in
autophagy are associated with a number
of disorders, including cancer, neurodegeneration, muscle disease and inflammation. There is a rapidly growing need
among scientists to have tools and assays
that allow one to accurately detect autophagy and study its function in mammalian systems.2,3 LC3 is a ubiquitin-like
molecule that is conjugated to phosphatidylethanolamine by Atg7 to form LC3-II
upon autophagic stimulation.1 LC3-II is
localized to autophagic structures including phagophores, autophagosomes and
autolysosomes. Cellular LC3-II levels correlate with autophagosome number and
measuring the conversion of LC3-I to
LC3-II by immunoblot is a reliable assay
for autophagosome formation.3 However,
there are limitations to the interpretation
of LC3-II levels since LC3-II is both produced and degraded during autophagy. To
circumvent this, it has been proposed that
LC3-II levels should only be evaluated
in the presence and absence of inhibitors
which block autophagosome and hence
LC3-II degradation.2,4 This method has
become the mainstay of LC3-II analysis
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Figure 1. (A) 3-month-old male mice were treated with vehicle, 50 mg/kg/day chloroquine, 0.4
mg/kg/day colchicine or 2 mg/kg/day vinblastine for two days and tibialis anterior (TA) muscle
lysates were evaluated by LC3 immunoblot. Actin is shown as a loading control. Blot is representative of 3 independent experiments. (B) TA from similarly treated mice as in (A) was subjected
to immunofluorescence using an LC3 antibody. Colchicine treated mice had an increase in LC3
positive puncta. Images were taken at the same camera setting and exposure time. Scale is 40
mM. (C) The TA muscle from 3-month-old male mice was electroporated with a tandemly tagged
mCherry-GFP-LC3 reporter construct. Mice were either treated for two days with vehicle or 0.4
mg/kg/day colchicine. Vehicle treated mice had diffuse LC3 fluorescence while colchicine treated
mice generated GFP and mCherry positive co-localizing puncta consistent with colchicine impairing autophagosome maturation to an acidic organelle. Scale is 25 mM.

in cell culture models and is discussed in
detail in several review papers.2,4
In order to adapt this technique to an
in vivo mammalian model such as mice,
we screened several lysomotropic and/or
autophagosome-lysosome fusion inhibitors for their ability to increase basal
LC3-II protein levels in mouse skeletal
muscle. These preliminary studies identified colchicine as a safe, quick-acting and
potent compound that increased LC3-II
levels >100%. In vivo blockage of LC3-II
degradation with colchicine enabled us
to quantitate the induction of autophagy
following nutrient deprivation or with the
mTOR inhibitors rapamycin and temsirolimus in mature skeletal muscle. The following manuscript details how to measure
in vivo autophagic flux in mouse skeletal
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muscle and provides examples of the utility of this assay.
Results
Chronic intoxication of patients and mice
with chloroquine, colchicine or vinblastine results in similar vacuolar myopathies.5 The pathogenic mechanism is
presumed to be a decrease in lysosomal
protein degradation secondary to impaired
autophagosome-lysosome fusion, diminished delivery of proteolytic enzymes to
the lysosome or deacidification of the lysosome. We reasoned that these drugs may
be able to effectively block autophagosome
degradation in vivo. With this premise, we
treated 3-month-old male mice with intraperitoneal (i.p.) vehicle, 50 mg/kg/day
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chloroquine, 0.4 mg/kg/day colchicine or
2 mg/kg/day vinblastine for two days and
then isolated tibialis anterior (TA) muscle.
No weight loss or distress was seen after
two days treatment with any of the three
drugs. Moreover, there was no evidence of
myopathic features or vacuolization in the
skeletal muscle by routine histopathology
(not shown). The TA was homogenized
and the resultant lysate was subjected to
SDS-PAGE and immunoblotted with an
antibody to LC3. The levels of LC3-II
were significantly elevated in the colchicine and vinblastine treated mice (Fig.
1A). This increase in LC3-II correlated
with a significant increase in LC3 positive
puncta as demonstrated in untreated compared with 2-day colchicine-treated mouse
skeletal muscle via immunhistochemistry
using an LC3 specific antibody (Fig. 1B).
p62 levels were unchanged at this same
timepoint (see colchicine-treated animals
from blots in Figs. 2A, 3A and D). Longer
treatments with all three drugs resulted in
only a modest further increase in LC3-II
levels and significantly increased levels of
p62 (not shown). In addition, longer treatment with vinblastine and chloroquine
resulted in significantly more animal
toxicity with weight loss and death after
5–7 days. This was not seen with chronic
colchicine treatment for an additional 10
days (longest time point evaluated). The
addition of vinblastine or chloroquine to
i.p. colchicine treatment was also not tolerated by the animals.
To confirm that colchicine treatment
did indeed block autophagosome degradation (i.e., fusion of the autophagosome with the lysosome), we utilized a
tandemly tagged mCherry-GFP-LC3
reporter construct.6 This reporter fluoresces green and red in the neutral environment of an autophagosome and red
in the acidic environment of an autolysosome or other acidic organelle. This
construct was electroporated into the TA
muscle of 3-month-old male mice and
allowed to express for seven days. On
day 5, mice were treated with saline or
0.4 mg/kg i.p. colchicine for two days.
TA muscle was harvested and sectioned.
Untreated mouse muscle had diffuse
green and red fluorescence throughout
the myofiber with no visible puncta as
would be expected for an LC3 protein
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that is not present on an autophagic structure (Fig. 1C). In contrast, two days of
colchicine treatment generated myofibers
with multiple dual fluorescing GFP and
mCherry positive puncta consistent with
autophagosomes that have not matured
to autolysosomes and become acidified
(Fig. 1C). In nonelectroporated myofibers, colchicine induced more LC3 positive puncta than Lamp2 positive puncta
and LC3 and Lamp2 did not co-localize
(not shown). These data further support
that two days of 0.4 mg/kg i.p. colchicine
is able to block autophagosome degradation in mouse skeletal muscle and this
dose was employed for all subsequent
experiments.
To see if the addition of colchicine
would allow us to quantitate autophagic
flux in vivo, we induced autophagy in mice
by depriving them of food for two days.
Four different cohorts of mice were used
(untreated, colchicine treated, starved
and starved plus colchicine treated) and
TA, gastrocnemius and quadriceps muscle
were harvested. Starved mice lost >10% of
their body weight over the two-day period
confirming that they were in fact nutrient
deprived. Muscle lysates were subjected
to SDS-PAGE and LC3 immunoblot.
Consistent with our previous experiment,
colchicine treatment increased the level
of LC3-II by >100%. Starvation alone
did not significantly increase LC3-II levels; however, starvation plus colchicine
increased LC3-II levels above that seen
with colchicine alone in all three muscles
(Fig. 2A and B and not shown).
It was previously reported that the
mTOR inhibitor rapamycin only modestly enhanced autophagy in cultured
myotubes.7 We confirmed this finding in differentiated C2C12 myotubes
using an in vitro autophagic flux assay.
Differentiated C2C12 cells were treated
with 10 µg/mL rapamycin and rapamycin with 200 nM bafilomycinA1. At this
dose of rapamycin we inhibited mTOR as
assessed by the phosphorylation of ribosomal protein S6 in myotubes, and slightly
increased the levels of LC3-II above that
seen with bafilomycinA1 alone (Fig. 3A).
In contrast, the corollary experiment done
in vivo with a colchicine “block” demonstrated a significant increase in LC3-II
when mice were treated for seven days
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Figure 2. (A) Similar mice were treated with vehicle, 0.4 mg/kg/day colchicine, nutrient deprivation (starvation) or nutrient deprivation plus 0.4 mg/kg/day colchicine for two days. TA muscle
lysates were evaluated by LC3 and p62 immunoblot. Note that colchicine treatment significantly
increases LC3-II levels. These levels are augmented by nutrient deprivation. Blot is representative
of three independent experiments. (B) LC3-II/actin ratios were quantitated via densitometry from
six mice per treatment condition. Error bars represent standard error and **denote p values of
<0.005 as obtained by student paired t-test.

with 10 mg/kg/day i.p. rapamycin (Fig.
3B and C). This was similar to that seen
when mice were treated for 7 days with
20 mg/kg/day of the rapamycin analog, temsirolimus/CCI-779 (Fig. 3D).
Interestingly, in both cases the increase
in LC3-II was not apparent without the
addition of colchicine for two days. As
expected both rapamycin and temsirolimus were able to decrease the phosphorylation of ribosomal protein S6 consistent
with their primary effect on the mTOR
pathway (Fig. 3B and D).
We wondered if the in vivo autophagic flux assay would be able to answer
whether autophagy is activated in skeletal muscle following denervation. It has
been previously reported that autophagy
is upregulated late in denervation-induced
atrophy.7,8 Therefore, we evaluated
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whether autophagic flux was upregulated
after seven days neurogenic atrophy. To do
this, we performed a sham or complete sciatic nerve transaction in several cohorts of
mice treated with and without colchicine
for two days (Fig. 4A, outlines experimental design). Denervation-induced atrophy
was confirmed via routine muscle histopathology and showed multiple atrophic
angular fibers as compared to sham controls (Fig. 4B). TA muscle was harvested
seven days post-denervation. Some groups
received colchicine for two days prior to
animal sacrifice. With this strategy, we
confirmed that autophagy is upregulated
as assessed by an increase in LC3-I and
LC3-II levels and further established that
“autophagic flux” is increased in denervation-induced atrophy at seven days (Fig.
4C and D).
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Figure 3. (A) Differentiated C2C12 myotubes were treated with vehicle, 200 nM BafilomycinA1, 10 µg/mL rapamycin or 10 µg/mL rapamycin plus
200 nM BafilomycinA1 for 6 hours. Lysates were subjected to LC3 and p62 immunoblots. Rapamycin did not increase LC3-II levels further than that
seen with BafilomycinA1 alone. The same lysates were subjected to immunoblot with antibodies to phospho-S6 (Ser235/236) and S6 kinase demonstrating that rapamycin is capable of mTOR inhibition in these cells. Blot is representative of two independent experiments. (B) 3-month-old male mice
were treated with vehicle, 0.4 mg/kg/day colchicine for two days, 10 mg/kg/day rapamycin for 7 days or 10 mg/kg/day rapamycin for 7 days and 0.4
mg/kg/day colchicine for two days beginning on day 5 and TA lysates were subjected to immunoblotting with LC3, p62, phospho-S6, total S6 kinase or
actin. Blot is representative of four independent experiments. (C) LC3-II/actin ratios were quantitated via densitometry from eight mice per treatment
condition. Error bars represent standard error and **denote p values of <0.005 as obtained by student paired t-test. (D) A similar experiment to (B)
was performed using 20 mg/kg/day temsirolimus/CCI-779 instead of rapamycin. Note that the addition of temsirolimus/CCI-779 to colchicine further
increased LC3-II levels consistent with an enhancement in autophagic flux.

Discussion
We describe an in vivo autophagic flux
assay that uses colchicine to block autophagosome degradation in skeletal muscle.
Although the principles of the assay have
been described for cell culture,2,4 this
report broadens the utility of an autophagic flux assay to whole animal models.
Several key differences in these assays warrant further discussion. One necessary element of the in vitro autophagic flux assay is
that autophagosome degradation must be
completely blocked. It has been suggested
that bafilomycinA1 or other lysomotropic
agent be carefully titrated in vitro and that
different cell lines may require different
doses.4 Moreover, the addition of a second agent such as vinblastine to the optimal established dose of bafilomycinA1
can help confirm a complete “block” in
LC3-II degradation.4 We attempted this
in vivo. However, increasing doses of colchicine above 0.6 mg/kg/day had lethal
consequences as did the addition of other
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“blocking” agents. Therefore the interpretation of any result using colchicine in
vivo should consider the possibility that an
increase in LC3-II levels is secondary to
an additional blockage in autophagosome
maturation or lysosomal degradation. It is
important to note that nutrient deprivation and mTOR inhibition via rapamycin
or temsirolimus alone failed to increase the
levels of LC3-II suggesting that autophagic flux is not impaired by these treatments. In these instances colchicine did
not result in an additive effect (as would
be expected if starvation or rapamycin
resulted in a decrease in autophagic flux)
but instead colchicine treatment revealed
an increase in autophagic flux that was not
readily apparent with rapamycin or starvation alone.
It is notable that p62 levels were
unchanged following two days of in vivo
colchicine treatment whereas LC3-II levels significantly increased. This difference
was not seen in bafilomycinA1 treated
myotubes where both p62 and LC3-II levels increased similarly (Fig. 3A). Chronic
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treatment of mice with colchicine (>five
days) did lead to an increase in p62 protein levels (not shown). Perhaps the differential accumulation of LC3-II versus
p62 under conditions of autophagic block
highlights the distinct autophagic degradation kinetics of these two substrates in
mature skeletal muscle as compared to cell
culture. For example, p62 associates with
myofibrillar proteins such as titin and may
turnover more slowly than LC3-II.9
Another critical difference between an
in vitro and in vivo autophagic flux assay
is the time period of bafilomycinA1 versus
colchicine treatment. Whereas in cultured
cells one can treat with bafilomycinA1 for
short periods of time (e.g., 2–4 hours) and
achieve a block in autophagosome-lysosome fusion, this is not feasible in vivo. It is
conceivable that the prolonged use of colchicine to block autophagosome-lysosome
fusion in vivo compensatorily leads to an
upregulation in autophagy. However, this
does not seem to be apparent at two days
since there is no increase in LC3-I levels.
Both LC3-I and LC3-II levels are elevated
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Figure 4. Denervation-induced atrophy
enhances autophagic flux. (A) Schematic of
experimental design to assess autophagic
flux post denervation. Briefly, 3-month-old
male mice had a sham or complete sciatic
nerve transaction (denervation) for seven
days prior to muscle harvesting. Mice were
also treated with vehicle or 0.4 mg/kg/day
colchicine for two days prior to harvesting.
(B) Hematoxylin and eosin staining of TA
muscle from 7 day sham or denervated mice.
Note an increase in atrophic angular fibers in
denervated animal (arrows). Scale is 40 mM.
(C) TA muscle lysates from each group were
subjected to LC3, p62 or actin immunoblots.
Blots are representative of two independent
experiments. There was an augmentation of
LC3-II levels above that seen with colchicine alone after seven days of denervation.
(D) LC3-II/actin ratios were quantitated via
densitometry from muscle lysates from two
independent experiments with two mice per
treatment condition. Error bars represent
standard error and *denote p values of <0.05
as obtained by student paired t-test.

when mice are treated with colchicine
beyond five days suggesting that both an
enhancement and blockage of autophagy
is occurring with prolonged treatment
(not shown).
One important aspect of this assay
is the use of colchicine as a blocker of
autophagosome degradation. We selected
colchicine for several reasons. (1) colchicine is inexpensive and has excellent in
vivo pharmokinetics; (2) colchicine is
well tolerated by mice unlike chloroquine,
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bafilomycinA1 and vinblastine which
have significant toxicities; and (3) the
increase in LC3-II protein levels occurred
rapidly in skeletal muscle within two
days of colchicine treatment. Colchicine
inhibits microtubule polymerization by
binding to tubulin.5 This mechanism of
action has led to its use as a chemotherapeutic and anti-inflammatory agent since
it targets dividing cells and can inhibit
neutrophil motility. Chronic treatment of
mice or patients with colchicine can cause
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a reversible vacuolar myopathy.5 Muscle
tissue from colchicine myopathy patients
characteristically contains vacuoles that
label with acid hydrolases suggesting that
they are lysosomal in origin.5 This suggests
that skeletal muscle may be particularly
sensitive to the autophagosome-lysosome
fusion effects of colchicine.
Our in vivo autophagic flux assay was
able to detect an increase in autophagy
following seven days of treatment with
the mTOR inhibitors rapamycin or temsirolimus. Previously it had not been well
established that these drugs were able
to stimulate autophagic flux in skeletal
muscle. In fact it had been suggested that
rapamycin was not a potent activator of
autophagy in skeletal muscle.7 Our data
would suggest that mTOR inhibition can
activate autophagy similar to that seen
with nutrient deprivation. This data raises
the possibility that an in vivo autophagic
flux may validate the efficacy of autophagy enhancing drugs that fail to significantly induce autophagy in vitro. Finally,
our assay was able to detect an increase
in autophagic flux following denervation
induced atrophy. Consistent with previous
reports looking at LC3-II protein levels
and autophagy related transcript changes,
we found that autophagy was activated
after seven days of denervation.7,8 This
finding further validates the utility of our
in vivo autophagic flux assay.
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Materials and Methods
Reagents and antibodies. Rapamycin
(R-5000)
and
Temsirolimus/CCI779 (T-8040) were purchased from
LC Laboratories (www.LCLabs.com).
BafilomycinA1 (B1793), chloroquine
diphosphate (C6628), colchicine (C9754)
and vinblastine (V1377) were purchased
from Sigma-Aldrich (www.sigmaaldrich.com). Anti-LC3B (L7543), p62
(P0067) and actin (A2066) polyclonal
antibodies were purchased from SigmaAldrich, anti-phospho-S6 (ser235/236)
(2211S) and p70 S6K (9202L) polyclonal
antibodies were purchased from Cell
Signaling Technology (www.cellsignal.
com) and anti-Lamp2 (SC-18822) was
purchased from Santa Cruz (www.scbt.
com). All other reagents were purchased
from Sigma-Aldrich. Skeletal muscle histochemistry was performed as previously
described.10
In vivo electroporation. Mice were
anesthetized using pentobarbital (50 mg
per kg body weight). The skin overlying the tibialis anterior (TA) muscle was
shaved, and the animals were injected
with 25 µg endotoxin free mCherry-GFPLC3 expression plasmid (provided by Dr.
Abhinav Diwan, Washington University)
diluted in sterile PBS to a volume of 50
µl by using a 0.5 ml syringe fitted with a
29-gauge needle. Two-needle array electrodes (450121) (Harvard Apparatus,
Holliston, MA) were inserted into the
muscle immediately after DNA delivery
for electroporation. The distance between
the electrodes was 5 mm, and the array
was inserted longitudinally relative to
the muscle fibers. In vivo electroporation
parameters were the following: voltage,
75 V; pulse length, 50 ms; # of pulse, 6
pulses; pulse interval, 200 msec; desired
field strength, 200 V/cm, given by a BTX
ECM830 Electro Square Porator. Animals
were allowed to recover for 5 days at which
time they were treated with i.p. vehicle or
0.4 mg/kg/day colchicine for two days.
Following treatment, TA muscle was
harvested and frozen in liquid nitrogen
cooled isopentane. 10 mM sections of TA
muscle were affixed to slides, treated for 10
minutes in ice cold acetone and mounted
with Prolong Gold + DAPI (Invitrogen;
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P36931). Specimens were examined using
a fluorescent microscope (Nikon 80i
upright) and Roper Scientific EZ monochrome CCD camera with deconvolution
software analysis (NIS Elements, Nikon).
Nonfluorescent images were taken with a
5 megapixel color CCD (Nikon). Image
processing and analysis were done with
(NIS Elements 4.0) software and Adobe
Photoshop CS3. All images were performed at room temperature using a 40X
objective.
Activation and blocking autophagy
in vivo. All animal experimental protocols were approved by the Animal Studies
Committee of Washington University
School of Medicine. Male C57BL6/J mice
(Jackson Laboratory) at 11∼12 weeks of
age were used for all experiments. Upon
arrival to Washington University School
of Medicine, mice were housed in a temperature-controlled environment with 12
hr light/dark cycles where they received
food and water ad libitum for a minimum
of 72 hours prior to any experimentation.
Rapamycin and temsirolimus were dissolved in 100% ethanol for a 62.5 mg/
ml stock solution and stored at -20°C.
Immediately prior to injection, rapamycin
and temsirolimus were diluted to 2.5 mg/
ml in vehicle solution (5% PEG 400, 5%
Tween 80 and 4% ethanol). 10 mg/kg/day
rapamycin, 20 mg/kg/day temsirolimus or
vehicle was i.p. injected to mice daily for
seven days. Nutrient deprivation was performed by removing food for 48 hr. Mice
had free access to drinking water. Mice
were weighed daily to confirm starvation.
0.4 mg/kg/day colchicine was dosed i.p.
in the last two days of the experiment.
Colchicine was dissolved in water and
stored at -20°C as a stock solution at a concentration of 4 mg/ml. On the day of treatment, colchicine was diluted to 0.1 mg/ml
in water prior to injection. Control mice
received an equal volume of i.p. water.
Western blot of muscle tissue. Animals
were anesthetized with an i.p. injection of
pentobarbital sodium (0.5 mg/kg) and
skeletal muscle was immediately dissected
and flash frozen in liquid nitrogen. Frozen
muscle was homogenized in 1 mL icecold RIPA buffer (150 mM NaCl; 10 mM
Tris-HCl, pH 7.2; 0.1% Triton X-100;
1% sodium deoxycholate; 5 mM EDTA)
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containing protease inhibitor cocktail
(Sigma-Aldrich) with glass grinding tubes
resting in an ice-water bath. The skeletal
muscle homogenate was then centrifuged
at 10,000 g for 10 min at 4°C. The protein concentration of the supernatant
was quantitated using the bicinchoninic
acid kit (Pierce Chemical; 23225) with
BSA as a standard and adjusted to 2 µg/
µl in RIPA buffer. This yields 800–1,000
µL of lysate. Aliquots of the lysate were
further solubilized in Laemmli sample
buffer and boiled for 5 min prior to SDSPAGE. 50 µg of protein was loaded and
resolved on 12% SDS-PAGE gels. Gel was
transferred to nitrocellulose membranes
(Trans-Blot, Bio-Rad) and the membrane
was blocked in a solution of 5% nonfat
dry milk in Tris-buffered saline containing 0.5% Tween-20 (TBS-T). Membranes
were incubated with a 1:2,000 dilution of
LC3B antibody in 1% milk and TBS-T, a
1:2,500 dilution of anti-p62 antibody, or
a 1:5,000 dilution of anti-actin antibody.
Blots were subsequently incubated with
peroxidase-conjugated secondary antibodies and immunoreactive proteins were
revealed using the ECL detection system
(GE Healthcare; RPN2209). Western
blot results were quantified by densitometric analysis using ImageJ software
(NIH). Western blots for phosphorylated
(Ser235/236) and p70 S6K were performed by a method analogous to that
described above.
Cell culture. The mouse myoblast
cell line C2C12 (American Type Culture
Collection) was maintained at 37°C in
5% CO2 in Dulbecco’s modified Eagle
Medium (GIBCO; 11965) supplemented
with 10% fetal bovine serum, 50 µg/ml
penicillin and 50 µg/ml streptomycin.
Cultures were induced to differentiate in
DMEM containing 2% horse serum for
five days. C2C12 myotubes grown on
six-well plates were treated with 10 µg/
mL rapamycin with and without 200
nM BafilomycinA1 for 6 hours. Cells
were washed with ice-cold PBS and then
scraped into RIPA buffer. Lysates were
centrifuged at 10,000 g for 10 min. All
western blots of C2C12 cells were processed in an analogous manner as mouse
muscle tissues and 20 µg of total proteins
were subjected to SDS-PAGE.
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